Sun Pharmaceutical Industries (BOM:524715, NSE:SUNPHARMA) reported Phase 2 trial results for SCD-044 in moderate to severe psoriasis and atopic dermatitis, according to a Tuesday filing on the local bourse.
Neither trial met the primary endpoint of 75% improvement by Week 16.
No major safety concerns were observed. The company is discontinuing SCD-044's development and will consider next steps with its partner.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。